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UCB were prospectively collected and eligible for final analy-
sis. Univariate and multivariate logistic regression models 
were applied to identify significant predictors of locally ad-
vanced tumor stage (pT3/4 and/or pN+) at RC. Internal valida-
tion was performed by bootstrapping. The decision curve 
analysis (DCA) was done to evaluate the clinical value.  Results: 
The distribution of tumor stages pT3/4, pN+ and pT3/4 and/
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 Abstract 
 Introduction: We aimed at developing and validating a pre-
cystectomy nomogram for the prediction of locally advanced 
urothelial carcinoma of the bladder (UCB) using clinicopatho-
logical parameters.  Materials and Methods: Multicenter data 
from 337 patients who underwent radical cystectomy (RC) for 
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or pN+ at RC was 44.2, 27.6 and 50.4%, respectively. Age (odds 
ratio (OR) 0.980; p < 0.001), advanced clinical tumor stage (cT3 
vs. cTa, cTis, cT1; OR 3.367; p < 0.001), presence of hydrone-
phrosis (OR 1.844; p = 0.043) and advanced tumor stage T3 
and/or N+ at CT imaging (OR 4.378; p < 0.001) were indepen-
dent predictors for pT3/4 and/or pN+ tumor stage. The predic-
tive accuracy of our nomogram for pT3/4 and/or pN+ at RC 
was 77.5%. DCA for predicting pT3/4 and/or pN+ at RC showed 
a clinical net benefit across all probability thresholds.  Conclu-
sion: We developed a nomogram for the prediction of locally 
advanced tumor stage pT3/4 and/or pN+ before RC using es-
tablished clinicopathological parameters. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Locally advanced tumor stages, including pathologic 
tumor stages pT3/4 and/or lymph node involvement 
(pN+) of urothelial carcinoma of the bladder (UCB) in 
patients undergoing radical cystectomy (RC) are associ-
ated with high treatment failure rates and reduced dis-
ease-specific survival  [1] . Clinical tumor stage based on 
transurethral resection of the bladder (TUR-BT) shows a 
considerable discrepancy when compared with the final 
pathologic stage obtained from the RC specimen. It has 
been demonstrated that almost 50% of patients treated 
with RC for clinical T1G3 UCB were upstaged to muscle-
invasive disease (MIBC) with 33.4% having non-organ-
confined disease  [2] . A reliable prediction of locally ad-
vanced stages of UCB may help improve risk stratifica-
tion and thus optimize the selection of candidates for 
multimodal treatment. The quality of treatment may be 
increased by better patient counseling on neoadjuvant 
chemotherapy (NAC), intraoperative strategies, for ex-
ample, extended lymphadenectomy, as well as nerve-
sparing techniques and choice of urinary diversion.
 Nomograms have been developed to predict locally 
advanced UCB or the likelihood of upstaging at the time 
of RC  [3, 4] . An external validation of 2 nomograms dem-
onstrated that the ability to predict pT3/4 stages or lymph 
node metastasis is limited and not necessarily conferrable 
to other cohorts  [3, 5] .
 In order to optimize the accuracy of existing predic-
tion tools, a statistical adjustment for relevant preopera-
tive parameters is important. Taking into account mul-
tiple clinical variables in the preoperative setting, we de-
veloped and validated a pre-cystectomy nomogram using 
preoperative variables in order to predict locally advanced 
UCB.
 Materials and Methods 
 Study Population 
 This study was approved by an institutional review board with 
all participating sites providing the necessary data-sharing agree-
ment within the ‘PROspective MulticEnTer RadIcal Cystectomy 
Series 2011’ (PROMETRICS 2011). A total of 18 European centers 
(15 German, 2 Austrian, and 1 Italian) prospectively collected data 
resulting in a database comprising 679 consecutive patients under-
going RC for muscle-invasive or high-risk bladder cancer between 
January 1, 2011 and December 31, 2011. A total of 342 patients 
(50.3%) were excluded due to missing information on lymphovas-
cular invasion (LVI) (n = 177) and muscularis propria (n = 119) at 
the time of last TUR-BT or evidence of distant metastases (n = 46). 
In total, 337 patients were eligible for the final analysis in the cur-
rent investigation.
 Data Assessment 
 Preoperative baseline patient characteristics were assessed and 
documented at admission for RC and included continuous vari-
ables such as age, gender and the number of TUR-BT. Categorical 
variables that were recorded at time of TUR-BT before RC were 
American Society of Anaesthesiologists Score (ASA, coded ASA1/2 
vs. ASA3/4), tumor stage (coded  ≥ cT3 vs. cT2 vs. cTa, cTis, cT1), 
concomitant carcinoma in situ (CIS, coded presence vs. absence), 
tumor grading (coded G2/3 vs. G1), LVI (coded presence vs. ab-
sence) and tumor stage depending on the presence of muscularis 
propria in the specimen (coded  ≥ cT2 vs. cTa, cTis, cT1 without 
muscularis propria and  ≥ cT2 vs. cTa, cTis, cT1 with presence of 
non-tumor-infiltrated muscularis propria). In addition, tumor 
stage (coded  ≥ T3 vs. <T3) and/or nodal stage (coded N+ vs. N–) 
at the computed tomography (CT), hydronephrosis (coded pres-
ence vs. absence) before RC and NAC (coded administered vs. not 
administered) were assessed as well. NAC was recorded only when 
patients received at least one complete cycle of chemotherapy. His-
topathological stages were classified according to the 2009 TNM 
classification  [6] . Histopathological evaluation was conducted by 
experienced uropathologists at each center according to standard 
protocols. Radiological evaluation in terms of clinical tumor and 
nodal stage was assessed by pre-RC imaging (CT) performed by 
experienced radiologists. The objective of our study was to evalu-
ate the impact of clinicopathological features obtained from the 
last TUR-BT and preoperative staging imaging before RC on the 
prediction of a locally advanced tumor stage pT3/4 and/or pN+.
 Statistical Analysis 
 Medians and interquartile ranges (IQR) were generated for 
continuously coded variables; frequencies and proportions were 
generated for categorical variables. The Mann-Whitney and 
 Chi-square test were used to assess differences in medians and pro-
portions, respectively. Univariate and multivariate logistic regres-
sion models were calculated to evaluate the impact of age, gender, 
 ASA-score, number of TUR-BTs before RC, tumor stage, CIS, tu-
mor grading, LVI, tumor stage depending on the presence of mus-
cularis propria in the specimen at the last TUR-BT before RC, tu-
mor and nodal stage at CT, preoperative hydronephrosis and the 
administration of NAC on the prediction of a locally advanced 
tumor stage pT3/4 and/or pN+ at RC. Backward elimination relied 
on Akaike’s information criterion to identify the most informative 
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the logistic regression coefficients, a nomogram to individually 
predict the risk of pT3/4 and/or pN+ tumor stage was developed. 
A calibration plot graphically explored the correlation between 
model predicted and observed regarding pT3/4 and/or pN+ at RC. 
The internal validity of the models was evaluated by bootstrapping. 
In 1,000 bootstrap samples, the coefficients of the final regression 
model were estimated and tested in the original sample. The dif-
ference between the coefficients in the original sample and boot-
strap samples as reflected by the slope index is the measure for the 
amount of ‘optimism’. Normally, slope values are located between 
0 and 1. A slope value of 1 means no optimism. PA of each model 
was quantified using the area under the receiver operating charac-
teristics curve  [8] .
 The decision curve analysis (DCA) was carried out to evaluate 
the clinical value of the prediction of pT3/4 and/or pN+ of our 
newly developed model vs. none, all and clinical tumor stage  ≥ 2 at 
the last TUR-BT before RC  [9, 10] . Analyses were conducted using 
the R statistical package (v.2.12.2) and the Statistical Package for 
Social Science 20.0 (SPSS Inc., Chicago, Ill., USA). All tests were 
two-sided with the statistical significance level set at p  ≤ 0.05.
 Results 
 Descriptive Characteristics 
 A total of 50.4% (n = 170) displayed a locally advanced 
tumor stage pT3/4 and/or pN+ at RC. The distribution of 
tumor stages pT3/4, pN+ and pT3/4 and/or pN+ at RC 
was 44.2, 27.6 and 50.4%, respectively.  Table 1 gives a de-
tailed illustration of the descriptive characteristics. The 
number of TUR-BTs before RC (p = 0.032), higher clini-
cal tumor stage (p < 0.001), presence of concomitant CIS 
(p = 0.037), presence of LVI (p = 0.011), higher clinical 
tumor stage in dependence of the muscularis propria (p < 
0.001), tumor stage <T3, nodal stage N– at CT (p < 0.001) 
and hydronephrosis before RC (p < 0.001) were signifi-
cantly associated with a locally advanced tumor stage 
pT3/4 and/or pN+, respectively ( table 1 ).
 Prediction of pT3/4 and/or pN+ 
 Clinical tumor stage  ≥ cT3 vs. cTa, cTis, cT1 (odds ra-
tio (OR) 4.342; p < 0.001) and clinical tumor stage cT2 vs. 
cTa, cTis, cT1 (OR 3.889; p = 0.030), concomitant CIS 
(OR 0.564; p = 0.031), LVI (OR 2.224; p = 0.010), clinical 
tumor stage in dependence of muscularis propria  ≥ cT2 
vs. cTa, cTis, cT1 with presence of tumor-free muscularis 
propria (OR 3.292; p < 0.001), hydronephrosis (OR 2.644; 
p < 0.001), tumor stage  ≥ T3 and/or N+ at CT (OR 5.053; 
p < 0.001), respectively, were significantly associated with 
pT3/4 and/or pN+ at RC in univariate logistic regression 
analysis ( table 2 a).
 In multivariate logistic regression analysis addressing 
the prediction of pT3/4 and/or pN+, age (OR 0.980; p < 
0.001), clinical tumor stage  ≥ cT3 vs. cTa, cTis, cT1 (OR 
3.367; p < 0.001), clinical tumor stage cT2 vs. cTa, cTis, 
cT1 (OR 3.476; p = 0.058), hydronephrosis (OR 1.844; p = 
0.043), and tumor stage  ≥ T3 and/or N+ at CT (OR 4.378; 
p  < 0.001), respectively, were the final variables of the 
model calculated in backward elimination ( table 2 b). The 
slopes of this model after 1,000 bootstrap samples within 
the internal validation were between 0.76 and 0.89. The 
inherent nomogram of our newly developed model can 
be seen in  figure 1 a showing a predictive accuracy (PA) 
of 77.5% in our study population.
 In addition, the DCA showed that the application of 
our nomogram predicting pT3/4 and/or pN+ at RC was 
associated with a higher net benefit over all thresholds 
compared to a clinical tumor stage  ≥ cT2 ( fig. 1 b).
 Compared to a reduced model (cT-stage of TUR-BT 
and radiological assessment), our nomogram always 
shows a net benefit above the 42% threshold ( fig. 1 c).
 Discussion 
 Locally advanced UCB (stage pT3/4 and/or pN+) is 
associated with reduced long-term survival following 
RC  [1, 11] . Staging before RC is often inaccurate and the 
discrepancy between staging based on TUR-BT and fi-
nal tumor stage of the cystectomy specimen represents 
a significant problem  [2, 12–14] . Among potential rea-
sons for this phenomenon are varying quality of 
 TUR-BT, low sensitivity of preoperative staging and in-
creasing time intervals between TUR-BT and RC  [1, 3] . 
An exact staging and prediction of advanced UCB is an 
essential requirement for adequate clinical decision 
making. We developed a pre-cystectomy nomogram in-
cluding age, clinical tumor stage  ≥ cT3, presence of hy-
dronephrosis before RC and tumor stage  ≥ T3 or N+ at 
CT imaging in order to predict pT3/4 and/or pN+ at RC. 
The PA of our nomogram was 77.5% and showed a net 
benefit by DCA.
 A pre-cystectomy nomogram for the prediction of ad-
vanced UCB stage has previously been developed by 
Karakiewicz et al.  [3] . Multivariate models for the predic-
tion of tumor stages pT3/4 and pN+ showed an accuracy 
of 75.7 and 63.1%, respectively. The nomograms were 
more accurate than the tumor stage at TUR-BT alone  [3] . 
May et al.  [5] externally validated both nomograms im-
plemented by Karakiewicz based on data of 2,477 pa-
tients of a German cohort treated by RC. They found a 
relatively low PA of 67.5 and 54.5% for the prediction of 
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Age at RC, years, median (IQR) 69 (62–76) 69 (62–76) 69 (62–76) 0.979
Gender 0.668
Male 278 (82.5) 142 (83.5) 136 (81.4)
Female 59 (17.5) 28 (16.5) 31 (18.6)
ASA-score 0.547
1 20 (5.9) 8 (4.7) 12 (7.2)
2 164 (48.7) 79 (46.5) 85 (50.9)
3 146 (43.3) 79 (46.5) 67 (40.1)
4 7 (2.1) 4 (2.4) 3 (1.8)
Number of TUR-BTs before RC, mean ± SD 1.80±1.36 1.71±1.32 1.88±1.40 0.032
Clinical tumor stage <0.001
cTa 18 (5.3) 3 (1.8) 15 (9.0)
cTis 11 (3.3) 2 (1.2) 9 (5.4)
cT1 73 (21.7) 22 (12.9) 51 (30.5)
cT2 223 (66.2) 136 (80.0) 87 (52.1)
cT3 3 (0.9) 1 (0.6) 2 (1.2)
cT4 9 (2.7) 6 (3.5) 3 (1.8)
Concomitant CI S at last TUR-BT before RC
Present 76 (22.6) 30 (17.6) 46 (27.5) 0.037
Absent 261 (77.4) 140 (82.4) 121 (72.5)
Grading at last TUR-BT before RC 0.758
G1/G2 49 (14.5) 26 (15.3) 23 (13.8)
G3 288 (85.5) 144 (84.7) 144 (86.2)
LVI at last TUR-BT before RC
Present 54 (16.0) 36 (21.2) 18 (10.8) 0.011
Absent 283 (84) 134 (78.8) 149 (89.2)
Clinical tumor stage in dependence of muscularis propria <0.001
cTa, cTis, cT1 without muscularis propria 53 (15.7) 17 (10.0) 36 (21.6)
cTa, cTis, cT1 with presence of tumor-free muscularis propria 49 (14.5) 10 (5.9) 39 (23.4)
≥cT2 235 (69.7) 143 (84.1) 92 (55.1)
Tumor stage at CT before RC
<T3 255 (75.7) 109 (64.1) 146 (87.4) <0.001
≥T3 82 (24.3) 61 (35.9) 21 (12.6)
Nodal stage at CT before RC
N– 279 (82.8) 123 (72.4) 156 (93.4) <0.001
N+ 58 (17.2) 47 (27.6) 11 (6.6)
Tumor and nodal stage at CT before RC <0.001
<T3 and N– 229 (68.0) 29 (40.3) 200 (75.5)
≥T3 and N+ 108 (32.0) 43 (59.7) 65 (24.5)
Hydronephrosis before RC
Present 79 (23.4) 54 (31.8) 25 (15.0) <0.001
Absent 258 (76.6) 116 (68.2) 142 (85.0)
NAC 0.722
Administered 7 (2.1) 3 (1.8) 4 (2.4)
Not administered 330 (97.9) 167 (98.2) 163 (97.6)
 Figures in parentheses are percentages.
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tive ability of both nomograms presented by Karakiewicz 
was not conferrable to patients of the German cohort be-
cause the number of locally advanced UCB was underes-
timated  [5] . The authors stated that the development of 
new models to predict advanced UCB with a higher PA 
is needed.
 We considered additional clinical parameters for the 
generation of our model: LVI at last TUR-BT before RC, 
clinical tumor stage according to muscularis propria 
( ≥ cT2 vs. cTa, cTis, cT1 without muscularis propria; 
 ≥ cT2 vs. cTa, cTis, cT1 with presence of non-tumor-in-
filtrated muscularis propria), tumor and nodal stage at 
CT imaging ( ≥ T3 vs.  ≤ T3 or N+ vs. N–) and the presence 
of hydronephrosis before RC. The PA was increased by 
integrating these factors, which are part of routine diag-
nostic algorithms. It has been shown that the presence of 
LVI in TUR-BT specimens was significantly associated 
with pT3/4 and/or pN+ only in univariate analysis (p = 
0.010). Green et al.  [4]  demonstrated that the presence of 
LVI in the TUR-BT specimen is associated with the pres-
ence of pN+ stage independently.
 Although the presence of LVI in TUR-BT was not an 
independent predictor in our final model, it may add rel-
evant information for the prediction of advanced tumor 
stages. Patients with cT2-tumor stage without LVI had a 
57.3% probability of pT3/4 and/or pN+ in the final path-
ological evaluation versus 75.6% in patients with cT2 and 
detected LVI (p = 0.027).
Tabl e 2. Prediction of pT3/4 and/or pN+ at RC
a Univariate logistic regression model addressing prediction of pT3/4 and/or pN+ at RC
Variables Prediction of pT3/4 and/or pN+ at RC
OR 95% confidence interval p value
lower upper
Age at RC (cont.) 1.002 0.981 1.024 0.846
Female gender (ref.: male) 0.865 0.493 1.518 0.614
Number of TUR-BTs before RC (cont.) 0.911 0.776 1.071 0.258
Clinical tumor stage
≥cT3 vs. cTa, cTis, cT1 4.342 2.593 7.272 <0.001
≥cT2 vs. cTa, cTis, cT1 3.889 1.138 13.292 0.030
Tumor grading G2/G3 at last TUR-BT before RC (ref.: G1) 0.885 0.482 1.623 0.692
Presence of concomitant CIS at last TUR-BT before RC (ref.: absence) 0.564 0.335 0.948 0.031
Presence of LVI at last TUR-BT before RC (ref.: absence) 2.224 1.206 4.101 0.010
Clinical tumor stage in dependence of muscularis propria
≥cT2 vs. cTa, cTis, cT1 without muscularis propria 0.543 0.220 1.339 0.185
≥cT2 vs. cTa, cTis, cT1 with presence of tumor-free muscularis propria 3.292 1.747 6.202 <0.001
Presence of hydronephrosis before RC (ref.: absence) 2.644 1.550 4.509 <0.001
ASA-score 3/4 at RC (ref.: ASA-score 1/2) 1.322 0.860 2.032 0.203
No administration of NAC (ref.: administration) 0.732 0.161 3.322 0.686
Tumor stage ≥T3 and/or N+ at CT before RC (ref.: <T3 and pN–) 5.053 3.019 8.460 <0.001
b Final step of the backward eliminated multivariate regression model addressing the prediction of pT3/4 and/or pN+ at RC
Variables Prediction of tumor stage pT3/4 and/or nodal stage pN+ at RC
OR  95% confidence interval p value
lower upper
Age at RC (cont.) 0.980 0.973 0.987 <0.001
Clinical tumor stage 
≥cT3 vs. cTa, cTis, cT1 3.367 1.977 5.733 <0.001
cT2 vs. cTa, cTis, cT1 3.476 0.959 12.604 0.058
Presence of hydronephrosis at RC (ref.: absence) 1.844 1.019 3.336 0.043
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 The quality of TUR-BT and related clinical tumor 
stage plays an important role for the prediction of defi-
nite tumor stage. For an improved accuracy of the clini-
cal tumor stage in TUR-BT specimens, we included the 
presence of a tumor-free muscularis propria in TUR-BT 
specimens. We discovered that the factor  ≥ cT2 vs. cTa, 
cTis, cT1 with the presence of tumor-free muscularis 
propria was significantly associated with pT3/4 and/or 
pN+ only in univariate analysis (p < 0.001). In our mul-
tivariate model, lower patient age was an independent 
predictor for advanced tumor stage (OR 0.980; p < 0.001). 
This fact is contrary to the results of Karakiewicz et al. 
 [3] . One might conclude that younger patients with 
MIBC in particular may benefit from an early RC be-
cause of their higher probability of having advanced tu-
mor stage.
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 Fig. 1.  a Nomogram for the prediction of pT3/4 and/or pN+. To 
obtain the nomogram-predicted probability of pT3/4 and/or pN+ 
at RC, locate the patient values on each axis. Draw a vertical line to 
the ‘points’-axis to determine how many points are attributed for 
each variable value. Add the points of all variables. Locate the sum 
on the ‘total points’ line to assess the individual probability of the 
respective stages at RC.  b DCA showing the net benefit associated 
with the use of the models for prediction of pT3/4 and/or pN+ at 
RC. Model 1 (dashed line) refers to our newly developed nomo-
gram. Model 2 (dotted line) refers to the prediction of pT3/4 and 
or pN+ according to the variable  ≥ cT2.  c DCA showing the net 
benefit associated with the use of the models for prediction of 
pT3/4 and/or pN+ at RC. Model 1 (dashed line) refers to our new-
ly developed nomogram. Model 2 (dotted line) refers to the predic-
tion of pT3/4 and or pN+ according to the reduced model (cT-
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 Considering the important role of modern imaging 
methods for clinical staging prior to RC, the integration 
of cT- and cN-stage by preoperative imaging appeared 
essential when generating our nomogram. In our cohort, 
an advanced tumor stage on preoperative CT imaging 
 ≥ T3 and/or N+ was an independent predictor for tumor 
stage pT3/4 and/or pN+ (OR 4.378; p  < 0.001) at RC. 
Stimson et al.  [15]  previously described the association of 
preoperative hydronephrosis with the presence of non-
organ-confined UCB with lymph node metastases at the 
time of RC. In our cohort, the presence of hydronephro-
sis  was identified as an independent predictor for ad-
vanced tumor stage pT3/4 and/or pN+ (OR 1.844; p = 
0.043).
 The use of a pre-cystectomy nomogram with a high PA 
regarding the presence of advanced tumor stages may 
help the clinician to decide whether or not to apply NAC. 
NAC may have a beneficial effect by downstaging and re-
ducing the probability of a positive surgical resection 
margin as well as in an early treatment of potential micro-
metastases  [16, 17]. Grossman et al. [18] demonstrated 
that patients with locally advanced UCB benefitted from 
NAC when compared to RC alone in the SWOG S8710 
study. Using low risk and high risk features, Culp et al. 
[19] also identified patients with a poor prognosis who 
are most likely to benefit from NAC. However, NAC is 
rarely practiced. Possible reasons for the underutilization 
of NAC remain still unclear but could be explained by 
concerns regarding efficacy and potential delay of RC. In 
a recent study only 12% of the patients with clinical tumor 
stages pT2-T4aN0M0 received NAC whereas 22% re-
ceived adjuvant chemotherapy  [20] . Similarly, only a 
small proportion of patients received NAC in the present 
study: altogether, 7 patients (2.1%) with NAC were in-
cluded in the study population. A sensitivity analysis of 
the 330 patients without NAC (data not shown) showed 
the same results as mentioned above.
 This study is limited by the heterogeneous cohort com-
posed by patients treated at different centers in  Germany, 
Austria and Italy with different surgical practices such as 
extent of lymphadenectomy, histopathological assessment 
or quality of TUR-BT. Another limitation displays the lack 
of a standard template of lymph node dissection. However, 
pelvic lymph node dissection was performed routinely and 
the extension of the dissection was based on preoperative 
CT scan and suspicious intraoperative findings. Other 
 important limitations were the lack of a central pathology 
and radiology review as well as the differences in clinical 
pathways, postoperative monitoring and follow-up.
 Conclusion 
 We developed a new nomogram for the prediction of 
locally advanced tumor stage pT3/4 and/or pN+ before 
RC using established clinicopathological parameters. The 
high PA and easy application may allow the use of our 
nomogram in daily clinical practice. An external valida-
tion of our model is required.
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